PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663488
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663488
Bioresorbable Scaffolds Market size was valued at US$ 1,892.32 Million in 2024, expanding at a CAGR of 19.90% from 2025 to 2032.
The bioresorbable scaffolds market focuses on medical devices designed to provide temporary support to a damaged artery and gradually dissolve, eliminating the need for permanent implants. The increasing prevalence of cardiovascular diseases and advancements in minimally invasive procedures are key factors propelling market growth. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for over 17 million deaths annually, which underscores the need for innovative treatment solutions like bioresorbable scaffolds. However, challenges such as high costs and concerns about long-term efficacy restrain wider adoption. Despite these hurdles, ongoing research and development activities present significant opportunities, particularly in developing more durable and biocompatible materials. Regulatory approvals, such as the U.S. FDA's clearance of next-generation bioresorbable scaffolds, are also paving the way for market expansion. Additionally, the increasing focus on personalized medicine and growing awareness about the benefits of bioresorbable scaffolds over traditional stents are expected to fuel demand in the coming years.
Bioresorbable Scaffolds Market- Market Dynamics
Rising Cardiovascular Disease Incidence Drives Bioresorbable Scaffolds Market Growth
The rising incidence of cardiovascular diseases is a significant driver of growth in the bioresorbable scaffolds market, as healthcare systems worldwide seek advanced treatment options. According to the American Heart Association, nearly 20 million people die annually from cardiovascular-related conditions, creating a pressing need for innovative medical devices. Bioresorbable scaffolds, which provide temporary artery support and gradually dissolve, offer a promising alternative to permanent stents. Notably, hospitals in Europe have successfully adopted these scaffolds, reducing long-term complications associated with metallic implants. Regulatory bodies like the U.S. FDA have approved new-generation bioresorbable scaffolds, further supporting their adoption. With ongoing advancements in material science and increased focus on minimally invasive procedures, bioresorbable scaffolds are poised to become a key component in cardiovascular care.
Bioresorbable Scaffolds Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.90% over the forecast period (2025-2032)
Based on Material Type segmentation, Polymer-based scaffolds were predicted to show maximum market share in the year 2024
Based on Type segmentation, Drug-eluting coronary scaffolds were the leading Type in 2024
Based on Application segmentation, Coronary Artery Disease was the leading Application in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Bioresorbable Scaffolds Market is segmented on the basis of Material Type, Type, Application, End-User, and Region.
The market is divided into four categories based on Material Type: Polymer-Based Scaffolds, Metal-Based Scaffolds, Polycarbonate Scaffolds, and Absorbable Magnesium Stents (AMS). Polymer-based scaffolds are prioritized due to their high biocompatibility and widespread use in cardiovascular treatments. Absorbable Magnesium Stent (AMS) follows, offering promising results in bioresorption. Metal-based scaffolds rank next, while polycarbonate scaffolds are emerging as a niche segment.
The market is divided into five categories based on Type: Drug Eluting Coronary Scaffolds, Sirolimus-Eluting Devices, Everolimus-Eluting Devices, Paclitaxel-Eluting Devices, and Novolimus-Eluting Devices. Drug-eluting coronary scaffolds lead, particularly everolimus-eluting devices due to their proven efficacy and safety profiles. Sirolimus-eluting devices follow closely, known for reducing restenosis rates. Paclitaxel-eluting and novolimus-eluting devices rank next, offering alternative options for targeted drug delivery.
Bioresorbable Scaffolds Market- Geographical Insights
The bioresorbable scaffolds market displays varied growth across different regions, with North America leading due to a high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. The U.S., in particular, is a significant market, driven by advanced research and the presence of key industry players. Europe follows closely, with countries like Germany and the UK at the forefront, supported by robust healthcare systems and increasing adoption of minimally invasive procedures. The region also benefits from favorable regulatory frameworks and government initiatives promoting innovative medical devices. Asia-Pacific is emerging as a rapidly growing market, fueled by rising healthcare expenditure, increasing awareness about advanced cardiovascular treatments, and a high burden of cardiovascular diseases in countries like China and India. Additionally, improving healthcare infrastructure and growing medical tourism in the region contribute to market expansion. Latin America and the Middle East & Africa are also witnessing gradual growth, driven by improving access to healthcare and rising investment in modern medical technologies. As awareness and availability of bioresorbable scaffolds expand globally, these regions are expected to play a more significant role in the market's future growth.
The biopharmaceutical logistics market is highly competitive, with major players focusing on expanding their capabilities and enhancing service offerings to meet the stringent requirements of the pharmaceutical industry. Companies such as DHL, FedEx, and UPS dominate the market, leveraging their extensive global networks and expertise in cold chain logistics to ensure the safe and timely delivery of temperature-sensitive products. DHL's investment in advanced temperature-controlled facilities and FedEx's development of specialized packaging solutions highlight the industry's push for innovation. Additionally, regional players like Kerry Logistics and Sinotrans are gaining traction in Asia-Pacific, capitalizing on the growing demand for biopharmaceutical logistics in emerging markets. Collaborations and strategic partnerships are common, with logistics providers partnering with pharmaceutical companies to develop customized solutions. For instance, UPS's healthcare division has expanded its network of cold chain facilities to support the distribution of COVID-19 vaccines. The competitive landscape is further shaped by technological advancements, such as real-time tracking and data analytics, which enhance supply chain visibility and reliability, ensuring compliance with regulatory standards.
In October 2023, Reckitt and Mondi announced the launch of a new packaging made of paper which is made of 75% less plastic and will be used for packaging Finish dishwater tablets. The move is expected to eliminate the use of almost 2,000 tonnes of plastic annually once it is completely in action
In April 2024, The FDA approved the Esprit BTK, an everolimus-eluting bioresorbable scaffold for below-the-knee lesions. This marks a significant milestone in treating chronic limb-threatening ischemia, offering a dissolving solution that enhances patient outcomes compared to conventional methods.